Otonomy Unternehmenskultur

Dr. Jay B. Lichter, Ph.D., serves as the Chief Executive Officer and President of Fortis Therapeutics, Inc. Dr. Lichter serves as Managing Director, Managing Partner and Partner of Avalon Ventures, LLC. Dr. Lichter has been with Avalon Ventures, LLC since 2007 and directs life sciences investing. He has been the Chief Executive Officer and Chairman of COI Pharmaceuticals Inc. since January 9, 2014. Dr. Lichter is the Founder of Afraxis, Inc. He serves as the Chief Executive Officer and President of Sova Pharmaceuticals, Inc. He is a Co-founder of Carolus Therapeutics, Inc. and serves as its Chairman. He co-founded Otonomy, Inc., in 2008 and served as its Chief Executive Officer until November 2010 and President until December 2010. Dr. Lichter served as Chief Executive Officer and President of ReVision Therapeutics, Inc. He served as the Chief Executive Officer and President of Afraxis, Inc. Dr. Lichter served as an Interim President and Chief Executive Officer of Synthorx Inc. until November 27, 2017. He served as Chief Executive Officer of Avelas BioSciences Inc. until January 09, 2014. He served as the Chief Executive of Carolus Therapeutics, Inc. He was directly responsible for or participated in licensing or merger and acquisition deals valued in excess of $1 billion. Dr. Lichter was a Venture Partner at the Avalon. He served as the President and Chief Executive Officer of Akesis Pharmaceuticals, Inc., from October 03, 2006 to June 2008 and October 03, 2006 to November 2008 respectively. Dr. Lichter served as the Chief Executive Officer and President at Zacharon Pharmaceuticals, Inc. Previously, Dr. Lichter served as Vice President and Vice President of Operations and Business Development at Sytera, Inc. He co-founded Sytera, Inc. in 2004. Dr. Lichter held various roles in Sytera, Inc. and was the inventor on key enabling intellectual property that led to its acquisition by Sirion Therapeutics, Inc. in July 2006. He co-founded Sequana Therapeutics in 1993. Dr. Lichter held various management positions during his five years at Sequana Therapeutics. He served various roles within it including managing the genetics department (with over 40 scientists), working in business development and initiating the pharmacogenetics business unit. Dr. Lichter led the negotiations or participated in the development and management of collaborations with Glaxo (diabetes), Boehringer Mannheim (osteoporosis), Boehringer Ingleheim (asthma) and Parke-Davis (central nervous system). He served as an Executive Vice President of Business Development for Sequenom Inc. from November 2001 to 2004. Dr. Lichter negotiated strategic transactions with Bristol-Myers Squibb and Proctor & Gamble and served as the in-licensing manager for genomics and discovery central nervous system (CNS) research at Pfizer. He participated in seven other Pfizer-biotech collaborations and completed over 50 university licensing deals. Dr. Lichter also served as the Vice President of Pharmacogenetics at Serono Genetics Institute S.A. (formerly Genset SA), where he was responsible for managing Genset's collaboration with Abbott Labs and developing collaborations with Pharmacia and Upjohn. Prior to this, Dr. Lichter served as the President and Chief Executive Officer of XenoPharm, Inc., which he co-founded in 2000. From September 2000 to February 2001, Dr. Lichter served as the Vice President and Chief Business Officer at 454 Life Sciences Corporation from September 2000 to February 2001. Dr. Lichter serves as Chairman of the Board of Synthorx Inc. He serves as the Chairman of InCode BioPharmaceutics, Inc., and Afraxis, Inc. He has been Chairman of AristaMD since July 21, 2016. He has been Chairman of Avelas BioSciences, Inc. since January 09, 2014. He has been Chairman of the Board at Otonomy, Inc. since August 27, 2015. He serves as a Director of Sova Pharmaceuticals, Inc. Dr. Lichter serves as an Observer at Syndax Pharmaceuticals, Inc. He serves as a Director of Enlibrium, Inc. since December 3, 2015 and Afraxis, Inc. Dr. Lichter serves as a Director on the board of the John Wayne Cancer Institute and a Trustee and Chairman elect to Pacific Ridge School. He has been a Director of Otonomy, Inc. since May 2008. He serves as a Director of RQx Pharmaceuticals, Inc., and Avelas BioSciences, Inc. He serves as a Director at Carolus. Dr. Lichter served as a Director of ReVision Therapeutics, Inc. He served as the Chairman of Aratana Therapeutics, Inc. since October 4, 2012 until August 10, 2015 and served as its Director since December 2010 until August 10, 2015. He served as the Chairman of Akesis Pharmaceuticals, Inc. since June 2008 and also served as its Director. He served as a Director of Avalon Ventures and Zacharon Pharmaceuticals, Inc. Dr. Lichter has authored and co-authored numerous scientific publications. At Yale University he received broad training in the areas of Classical Human Genetics, Clinical Genetics and Bioinformatics. During Dr. Lichter's two-year tenure at Yale, he specifically focused on Cancer Genetics and the Genetics of Neuropsychiatric Diseases and authored over 20 scientific papers. In 1993, he received second postdoctoral position at the DuPont Merck Pharmaceutical Company, where he focused on Pharmacogenetics and identified genetic mutations in an important dopamine receptor involved in drug response and disease progression for schizophrenia. He is a seasoned biotechnology and pharmaceutical business executive with over 25 years of experience in management, scientific research and business development. Throughout his career, he has applied his exceptional combination of business acumen and deep technical knowledge to creating commercially successful biotech collaborations and identifying the commercial potential of scientific discoveries at their earliest stages. Dr. Lichter is the inventor on 260 patent and patent applications for six Avalon portfolio companies, including 78 issued patents. Dr. Lichter completed his Ph.D. in Biochemistry from University of Illinois in 1990 and earned his B.S. from University of Illinois in 1984. In 1992, he did postdoctoral research in Human Genetics at Yale University.

Dr. Allen F. Ryan, Ph.D., Co-founded Otonomy, Inc. Dr. Ryan is a Professor and serves as a Director of Research in the Division of Otolaryngology at UCSD, and also serves as a Director of Otolaryngology Research at the San Diego VA Medical Center. He is one of the scientific founders of Otonomy. His research areas include the development and regeneration of hair cells; mechanisms of damage and survival of hair cells; regulation of survival and neurite extension in cochlear neurons; and the biology of middle ear inflammation, tissue growth and recovery during otitis media. Dr. Ryan served as the President of the ARO. He serves as a Member of Advisory Panel of Otonomy, Inc. He served as a Member of the Advisory Council of the National Institute on Deafness and Other Communication Disorders at the NIH, the Tinnitus Research Consortium, and the Council of Scientific Trustees of the Deafness Research Foundation. He serves as a Member of the Collegium Oto-Rhino-Laryngologicum Amicitiae Sacrum, and in addition chairs the International Jury for this society. He serves on the Executive Committees at the UCSD Neuroscience and the UCSD/SDSU Audiology doctoral programs. He has published over 300 papers on these and other topics in auditory research. Dr. Ryan received his B.S in Biology from Stanford University, a joint Ph.D in Physiology cu Biophysics and Psychology from the University of Washington, and postdoctoral training at Northwestern University.

Dr. Dean Hakanson, M.D., has been the Chief Medical Officer at Otonomy, Inc. since April 1, 2015. Dr. Hakanson has more than 16 years of industry experience in medical affairs, market access and health economic research with leading pharmaceutical companies including Novartis, Bristol-Myers Squibb, Genentech and GlaxoSmithKline. Dr. Hakanson joins Otonomy from Novartis, where he served as the vice president and head of health economics & outcomes research (HE&OR) for U.S. medical and drug regulatory affairs, preceded by a role as the vice president and medical head of the west operating unit where he led a field-based medical organization. Previous to Novartis, he served as the vice president of healthcare access at Bristol-Myers Squibb and prior to this position he served as the head of value-based healthcare/payer field team at Genentech. He also previously held positions of increasing responsibility at GlaxoSmithKline and served as vice president, medical affairs commercial operations; preceded by roles as vice president of managed markets, national accounts; medical director, Cigna national account; and director, client and strategic alliance. Prior to joining GlaxoSmithKline, Dr. Hakanson served as a medical director and critical care physician at John C. Lincoln IDS in Phoenix, Ariz. Previous to this role, he serveD as a medical director and critical care physician at Tenet Healthcare Corporation in San Francisco, Calif. Dr. Hakanson is a diplomat of the American College of Physician Executives and diplomat of the American Board of Anesthesiology and American Society of Anesthesiologists. He obtained a medical degree from the University of Colorado School of Medicine and a bachelor's degree in cellular physiology and physics from the University of Denver.

Mr. Paul E. Cayer has been the Chief Financial Officer and Chief Business Officer of Otonomy, Inc. since October 2010 and October 2008 respectively and served as Principal Accounting Officer. Mr. Cayer served as Secretary of Otonomy, Inc. since February 2011 until July 2015. He served as Senior Vice President of Corporate Development of Verus Pharmaceuticals Inc. since June 2005. Mr. Cayer has more than 25 years of experience in the pharmaceutical, medical device and healthcare technology field. Mr. Cayer served as the Chief Financial Officer and Senior Vice President, Business Development of Targeted Molecules Corp. He has extensive experience in strategic planning, business development and fund-raising for technology-based companies. During the past three years, Mr. Cayer has worked with several start-up companies in the healthcare and Internet arenas, serving as the Chief Executive Officer of ewomba.com. He was responsible for the commercialization of a proprietary cardiovascular drug at Gensia. He worked on the spin-out and venture financing of Gensia's Automedics subsidiary where he later served as a Vice President for commercial and business development activities. Mr. Cayer also worked as a consultant arranging venture financing and corporate partnerships for several start-up companies and in various positions at Gensia Pharmaceuticals, where he was responsible for the commercialization of a drug/device combination product. Prior to joining Gensia, Mr. Cayer worked in product development management and marketing at Acuson, business planning and development with Castle & Cooke and management consulting with Booz-Allen & Hamilton. Mr. Cayer received both his B.A. and M.B.A. from Harvard University.

Kathie Bishop serves as the Chief Scientific Officer of Otonomy, Inc. Kathie started at Otonomy, Inc in Jan of 2017. Kathie currently resides in the Greater San Diego Area.

Bob Savel serves as the Chief Technical Officer of Otonomy, Inc. Bob started at Otonomy, Inc in Jan of 2014. Bob currently resides in the Greater San Diego Area.

Carla Boren serves as the General Counsel, Head of Human Resources of Otonomy, Inc. Carla currently resides in the Greater San Diego Area.